A focused conversation on how neurotechnology is being applied across mental health, from neural biomarkers and digital phenotyping to neuromodulation and closed-loop approaches. The session explores where the science is translating into real products and trials, where limitations remain, and what this means for clinicians, founders, and investors working in the space.